Table 4.
Detailed cytology results of VaIN diagnosed in patients after hysterectomy and with no hysterectomy.
| VaIN | Cytology number (%) | Sensitivity (%) | |||||
|---|---|---|---|---|---|---|---|
| NILM | ASC-US | LSIL | ASC-H | HSIL | CA | ||
| VaIN with uterus | 132 (40.5%) | 71 (21.8%) | 108 (33.1%) | 6 (1.8%) | 8 (2.5%) | 1 (0.3%) | 59.5% |
| VaIN2/3 | 14 (41.2%) | 7 (20.6%) | 10 (29.4%) | 1 (2.9%) | 1 (2.9%) | 1 (2.9%) | 58.8% |
| VaIN1 | 118 (40.4%) | 64 (21.9%) | 98 (33.6%) | 5 (1.7%) | 7 (2.4%) | 0 (0.0%) | 59.6% |
|
| |||||||
| Only VaIN | 101 (47.6%) | 50 (23.6%) | 56 (26.4%) | 3 (1.4%) | 2 (0.9%) | 0 (0.0%) | 52.4% |
| VaIN2/3 | 11 (57.9%) | 4 (21.1%) | 3 (15.8%) | 1 (5.3%) | 0 (0.0%) | 0 (0.0%) | 42.1% |
| VaIN1 | 90 (46.6%) | 46 (23.8%) | 53 (27.5%) | 2 (1.0%) | 2 (1.0%) | 0 (0.0%) | 53.4% |
|
| |||||||
| Concomitant VaIN | 31 (27.2%) | 21 (18.4%) | 52 (45.6%) | 3 (2.6%) | 6 (5.3%) | 1 (0.9%) | 72.8% |
| VaIN2/3 | 3 (20.0%) | 3 (20.0%) | 7 (46.7%) | 0 (0.0%) | 1 (6.7%) | 1 (6.7%) | 80.0% |
| VaIN1 | 28 (28.3%) | 18 (18.2%) | 45 (45.5%) | 3 (3.0%) | 5 (5.1%) | 0 (0.0%) | 71.7% |
|
| |||||||
| VaIN after hysterectomy | 24 (30.4%) | 16 (20.3%) | 24 (30.4%) | 4 (5.1%) | 11 (13.9%) | 0 (0.0%) | 69.6% |
| VaIN2/3 | 5 (19.2%) | 3 (11.5%) | 3 (11.5%) | 4 (15.4%) | 11 (42.3%) | 0 (0.0%) | 80.8% |
| VaIN1 | 19 (35.8%) | 13 (24.5%) | 21 (39.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 64.2% |
VaIN: vaginal intraepithelial neoplasia; NILM: negative for intraepithelial lesion or malignancy; ASCUS: atypical squamous cells of undetermined significance; LSIL: low-grade squamous intraepithelial lesion; ASC-H: atypical squamous cells cannot exclude HSIL; HSIL: high-grade squamous intraepithelial lesion; CA: cancer.